ArticleFrontiers in neurology2025
Add-on efgartigimod in myasthenic crisis: a promising treatment option.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.Journal of neurology · 2026Article
- Case Report: Efficacy of efgartigimod for autonomic dysfunction in patients with autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 3 patients.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In myasthenia crisis (MC), plasma exchange (PE) and intravenous immunoglobulin (IVIG) are confirmed effective treatment options, but PE may not be available in time, and the response rate to IVIG is not always satisfactory. This study aimed to investigate whether addition of efgartigimod confers benefits in patients with MC. Methods: This real-world retrospective pilot study examined MC patients admitted to the First Affiliated Hospital of Sun Yat-sen University between August 2023 and May 2024, who were categorized into two groups: the traditional immunotherapy group ( Results: Totally 23 patients were recruited in the study. Total hospital stays, MV duration, and non-invasive ventilation time were shorter in the efgartigimod group compared with the traditional immunotherapy group; however, these differences were not statistically significant ( Conclusion: This suggests that efgartigimod may serve as an alternative option for MC patients or as a rescue treatment option for refractory individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.